



Dan Menichella is the CEO of CureVac AG, a company focused on mRNA-based therapeutics including oncology, rare diseases and prophylactic vaccines. He joined the company in January of 2017. Prior to becoming the CEO, Mr. Menichella was the CBO of CureVac AG and the CEO of CureVac Inc. He was responsible for four deals in 2017 including the 5 product immune oncology deal with Eli Lilly and Company.

Prior to CureVac, Mr. Menichella was at gene therapy company Bamboo Therapeutics which he helped sell to Pfizer. He has over 18 years of Senior Management experience in strategy and corporate development. Mr. Menichella has been in both public and private companies and actively helped two of the private companies go public by way of IPO. Mr. Menichella has an MBA from the University of North Carolina at Chapel Hill and an undergraduate degree in Economics from Harvard University.